These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24812389)

  • 21. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
    Subbaraman H; Schanz M; Trkola A
    Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations.
    Williams WB; Zhang J; Jiang C; Nicely NI; Fera D; Luo K; Moody MA; Liao HX; Alam SM; Kepler TB; Ramesh A; Wiehe K; Holland JA; Bradley T; Vandergrift N; Saunders KO; Parks R; Foulger A; Xia SM; Bonsignori M; Montefiori DC; Louder M; Eaton A; Santra S; Scearce R; Sutherland L; Newman A; Bouton-Verville H; Bowman C; Bomze H; Gao F; Marshall DJ; Whitesides JF; Nie X; Kelsoe G; Reed SG; Fox CB; Clary K; Koutsoukos M; Franco D; Mascola JR; Harrison SC; Haynes BF; Verkoczy L
    Nat Commun; 2017 Nov; 8(1):1732. PubMed ID: 29170366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pathway to HIV-1 neutralization breadth.
    Smith SA; Derdeyn CA
    Nat Med; 2015 Nov; 21(11):1246-7. PubMed ID: 26540383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modular synthesis of N-glycans and arrays for the hetero-ligand binding analysis of HIV antibodies.
    Shivatare SS; Chang SH; Tsai TI; Tseng SY; Shivatare VS; Lin YS; Cheng YY; Ren CT; Lee CC; Pawar S; Tsai CS; Shih HW; Zeng YF; Liang CH; Kwong PD; Burton DR; Wu CY; Wong CH
    Nat Chem; 2016 Apr; 8(4):338-46. PubMed ID: 27001729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies.
    Montefiori DC; Evans TG
    AIDS Res Hum Retroviruses; 1999 May; 15(8):689-98. PubMed ID: 10357464
    [No Abstract]   [Full Text] [Related]  

  • 26. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AIDS research. Novel antibody response may explain HIV vaccine success.
    Cohen J
    Science; 2011 Sep; 333(6049):1560. PubMed ID: 21921167
    [No Abstract]   [Full Text] [Related]  

  • 28. Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL.
    Kumar R; Pan R; Upadhyay C; Mayr L; Cohen S; Wang XH; Balasubramanian P; Nádas A; Seaman MS; Zolla-Pazner S; Gorny MK; Kong XP; Hioe CE
    J Virol; 2015 Sep; 89(17):9090-102. PubMed ID: 26109728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. B cell responses to HIV-1 infection and vaccination: pathways to preventing infection.
    Haynes BF; Moody MA; Liao HX; Verkoczy L; Tomaras GD
    Trends Mol Med; 2011 Feb; 17(2):108-16. PubMed ID: 21112250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates.
    Douagi I; Forsell MN; Sundling C; O'Dell S; Feng Y; Dosenovic P; Li Y; Seder R; Loré K; Mascola JR; Wyatt RT; Karlsson Hedestam GB
    J Virol; 2010 Feb; 84(4):1683-95. PubMed ID: 19955308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic labeling of HIV-1 envelope glycoprotein gp120 to elucidate the effect of gp120 glycosylation on antigen uptake.
    Sun L; Ishihara M; Middleton DR; Tiemeyer M; Avci FY
    J Biol Chem; 2018 Sep; 293(39):15178-15194. PubMed ID: 30115684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.
    Kumar R; Tuen M; Liu J; Nàdas A; Pan R; Kong X; Hioe CE
    Vaccine; 2013 Nov; 31(46):5413-21. PubMed ID: 24051158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advance in the structural analysis of HIV-1 envelope protein.
    Matsuda Z
    Sci China Life Sci; 2015 May; 58(5):420-4. PubMed ID: 25921945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
    Verkoczy L; Kelsoe G; Haynes BF
    PLoS Pathog; 2014 May; 10(5):e1004073. PubMed ID: 24853821
    [No Abstract]   [Full Text] [Related]  

  • 35. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.
    Gottardo R; Bailer RT; Korber BT; Gnanakaran S; Phillips J; Shen X; Tomaras GD; Turk E; Imholte G; Eckler L; Wenschuh H; Zerweck J; Greene K; Gao H; Berman PW; Francis D; Sinangil F; Lee C; Nitayaphan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Tartaglia J; Robb ML; Michael NL; Kim JH; Zolla-Pazner S; Haynes BF; Mascola JR; Self S; Gilbert P; Montefiori DC
    PLoS One; 2013; 8(9):e75665. PubMed ID: 24086607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.
    Walker LM; Simek MD; Priddy F; Gach JS; Wagner D; Zwick MB; Phogat SK; Poignard P; Burton DR
    PLoS Pathog; 2010 Aug; 6(8):e1001028. PubMed ID: 20700449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conformation-Dependent Interactions Between HIV-1 Envelope Glycoproteins and Broadly Neutralizing Antibodies.
    Flemming J; Wiesen L; Herschhorn A
    AIDS Res Hum Retroviruses; 2018 Sep; 34(9):794-803. PubMed ID: 29905080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralizing antibodies to HIV-1 induced by immunization.
    McCoy LE; Weiss RA
    J Exp Med; 2013 Feb; 210(2):209-23. PubMed ID: 23401570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AIDS vaccines: back to 'plan A'.
    Check E
    Nature; 2003 Jun; 423(6943):912-4. PubMed ID: 12827164
    [No Abstract]   [Full Text] [Related]  

  • 40. Recent strategies targeting HIV glycans in vaccine design.
    Horiya S; MacPherson IS; Krauss IJ
    Nat Chem Biol; 2014 Dec; 10(12):990-9. PubMed ID: 25393493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.